361 related articles for article (PubMed ID: 29958546)
21. PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Schönecker S; Brendel M; Palleis C; Beyer L; Höglinger GU; Schuh E; Rauchmann BS; Sauerbeck J; Rohrer G; Sonnenfeld S; Furukawa K; Ishiki A; Okamura N; Bartenstein P; Dieterich M; Bötzel K; Danek A; Rominger A; Levin J
Front Aging Neurosci; 2019; 11():249. PubMed ID: 31572166
[TBL] [Abstract][Full Text] [Related]
22. Distinct [
Schaeverbeke J; Evenepoel C; Declercq L; Gabel S; Meersmans K; Bruffaerts R; Adamczuk K; Dries E; Van Bouwel K; Sieben A; Pijnenburg Y; Peeters R; Bormans G; Van Laere K; Koole M; Dupont P; Vandenberghe R
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2342-2357. PubMed ID: 29946950
[TBL] [Abstract][Full Text] [Related]
23. Cerebral Tau Deposition in Comorbid Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis: An [18F]-Flortaucipir and 7T MRI Study.
Cheong I; Du Y; Smith G; Hua J; Li X; Pantelyat A
Neurodegener Dis; 2023; 23(3-4):35-42. PubMed ID: 38527450
[TBL] [Abstract][Full Text] [Related]
24. Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
Nihashi T; Sakurai K; Kato T; Iwata K; Kimura Y; Ikenuma H; Yamaoka A; Takeda A; Arahata Y; Washimi Y; Suzuki K; Bundo M; Sakurai T; Okamura N; Yanai K; Ito K; Nakamura A;
J Alzheimers Dis; 2022; 85(1):223-234. PubMed ID: 34776443
[TBL] [Abstract][Full Text] [Related]
25. Increased basal ganglia binding of
Smith R; Schain M; Nilsson C; Strandberg O; Olsson T; Hägerström D; Jögi J; Borroni E; Schöll M; Honer M; Hansson O
Mov Disord; 2017 Jan; 32(1):108-114. PubMed ID: 27709757
[TBL] [Abstract][Full Text] [Related]
26. [18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia.
Lee H; Seo S; Lee SY; Jeong HJ; Woo SH; Lee KM; Lee YB; Park KH; Heo JH; Yoon CW; Kang JM; Cho J; Okamura N; Furumoto S; Yanai K; Na DL; Ido T; Villemagne VL; Noh Y
Alzheimer Dis Assoc Disord; 2018; 32(1):62-69. PubMed ID: 29028649
[TBL] [Abstract][Full Text] [Related]
27. Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants.
Whitwell JL; Tosakulwong N; Botha H; Ali F; Clark HM; Duffy JR; Utianski RL; Stevens CA; Weigand SD; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Ahlskog JE; Dickson DW; Josephs KA
Neuroimage Clin; 2020; 25():102152. PubMed ID: 31935638
[TBL] [Abstract][Full Text] [Related]
28. First-in-Humans Evaluation of
Villemagne VL; Harada R; Doré V; Furumoto S; Mulligan R; Kudo Y; Burnham S; Krishnadas N; Bozinovski S; Huang K; Lopresti BJ; Yanai K; Rowe CC; Okamura N
J Nucl Med; 2022 Oct; 63(10):1551-1559. PubMed ID: 35086898
[TBL] [Abstract][Full Text] [Related]
29. Distribution Pattern of the Monoamine Oxidase B Ligand, 18F-THK5351, in the Healthy Brain.
Ishibashi K; Miura Y; Tago T; Toyohara J; Higashihara M; Iwata A; Ishii K
Clin Nucl Med; 2022 Jul; 47(7):e489-e495. PubMed ID: 35675140
[TBL] [Abstract][Full Text] [Related]
30. Dual tracer tau PET imaging reveals different molecular targets for
Chiotis K; Stenkrona P; Almkvist O; Stepanov V; Ferreira D; Arakawa R; Takano A; Westman E; Varrone A; Okamura N; Shimada H; Higuchi M; Halldin C; Nordberg A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1605-1617. PubMed ID: 29752516
[TBL] [Abstract][Full Text] [Related]
31. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
Cope TE; Rittman T; Borchert RJ; Jones PS; Vatansever D; Allinson K; Passamonti L; Vazquez Rodriguez P; Bevan-Jones WR; O'Brien JT; Rowe JB
Brain; 2018 Feb; 141(2):550-567. PubMed ID: 29293892
[TBL] [Abstract][Full Text] [Related]
32. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy.
Brendel M; Barthel H; van Eimeren T; Marek K; Beyer L; Song M; Palleis C; Gehmeyr M; Fietzek U; Respondek G; Sauerbeck J; Nitschmann A; Zach C; Hammes J; Barbe MT; Onur O; Jessen F; Saur D; Schroeter ML; Rumpf JJ; Rullmann M; Schildan A; Patt M; Neumaier B; Barret O; Madonia J; Russell DS; Stephens A; Roeber S; Herms J; Bötzel K; Classen J; Bartenstein P; Villemagne V; Levin J; Höglinger GU; Drzezga A; Seibyl J; Sabri O
JAMA Neurol; 2020 Nov; 77(11):1408-1419. PubMed ID: 33165511
[TBL] [Abstract][Full Text] [Related]
33. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.
Marquié M; Normandin MD; Meltzer AC; Siao Tick Chong M; Andrea NV; Antón-Fernández A; Klunk WE; Mathis CA; Ikonomovic MD; Debnath M; Bien EA; Vanderburg CR; Costantino I; Makaretz S; DeVos SL; Oakley DH; Gomperts SN; Growdon JH; Domoto-Reilly K; Lucente D; Dickerson BC; Frosch MP; Hyman BT; Johnson KA; Gómez-Isla T
Ann Neurol; 2017 Jan; 81(1):117-128. PubMed ID: 27997036
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the radiolabeled metabolite of tau PET tracer
Harada R; Furumoto S; Tago T; Furukawa K; Ishiki A; Tomita N; Iwata R; Tashiro M; Arai H; Yanai K; Kudo Y; Okamura N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2211-2218. PubMed ID: 27430946
[TBL] [Abstract][Full Text] [Related]
35. Quantitative evaluation of tau PET tracers
Chen J; Li Y; Pirraglia E; Okamura N; Rusinek H; de Leon MJ;
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1596-1604. PubMed ID: 29704038
[TBL] [Abstract][Full Text] [Related]
36. MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.
Whitwell JL; Tosakulwong N; Schwarz CG; Botha H; Senjem ML; Spychalla AJ; Ahlskog JE; Knopman DS; Petersen RC; Jack CR; Lowe VJ; Josephs KA
Mov Disord; 2019 Jan; 34(1):105-113. PubMed ID: 30468693
[TBL] [Abstract][Full Text] [Related]
37. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.
Vermeiren C; Motte P; Viot D; Mairet-Coello G; Courade JP; Citron M; Mercier J; Hannestad J; Gillard M
Mov Disord; 2018 Feb; 33(2):273-281. PubMed ID: 29278274
[TBL] [Abstract][Full Text] [Related]
38. [
Blazhenets G; Soleimani-Meigooni DN; Thomas W; Mundada N; Brendel M; Vento S; VandeVrede L; Heuer HW; Ljubenkov P; Rojas JC; Chen MK; Amuiri AN; Miller Z; Gorno-Tempini ML; Miller BL; Rosen HJ; Litvan I; Grossman M; Boeve B; Pantelyat A; Tartaglia MC; Irwin DJ; Dickerson BC; Baker SL; Boxer AL; Rabinovici GD; La Joie R
J Nucl Med; 2023 Dec; 64(12):1980-1989. PubMed ID: 37918868
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site.
Tago T; Toyohara J; Harada R; Furumoto S; Okamura N; Kudo Y; Takahashi-Fujigasaki J; Murayama S; Ishii K
Ann Nucl Med; 2019 Jun; 33(6):375-382. PubMed ID: 30796626
[TBL] [Abstract][Full Text] [Related]
40. Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.
Lockhart SN; Baker SL; Okamura N; Furukawa K; Ishiki A; Furumoto S; Tashiro M; Yanai K; Arai H; Kudo Y; Harada R; Tomita N; Hiraoka K; Watanuki S; Jagust WJ
PLoS One; 2016; 11(6):e0158460. PubMed ID: 27355840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
